Lantern Pharma Inc.

Lantern Pharma Inc. (NASDAQ: LTRX) is an artificial intelligence-focused biopharmaceutical company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. The company operates through its proprietary RADR® platform, an advanced artificial intelligence and machine learning system that currently encompasses more than 200 billion oncology-focused data points and employs a library of over 200 advanced machine learning algorithms. RADR® integrates multi-omic data, drug efficacy information, historical study data, scientific literature, phenotypic trial data, and mechanistic pathway information to identify biologically relevant genomic signatures correlated to drug response and identify cancer patients most likely to benefit from specific compounds.

Lantern's development portfolio includes three clinical-stage small molecule drug candidates: LP-300, LP-184, and LP-284, which target various solid tumors and hematological cancers including non-small cell lung cancer, triple negative breast cancer, glioblastoma, pancreatic cancer, and non-Hodgkin's lymphoma. The company established Starlight Therapeutics, a wholly-owned subsidiary, to focus exclusively on central nervous system and brain cancer indications. Additionally, Lantern is advancing an antibody-drug conjugate program in preclinical research optimization.

The company's strategy combines developing new drug candidates using its RADR® platform with rescuing previously failed drug candidates that demonstrate well-tolerated profiles and limited antitumor activity. This dual approach leverages artificial intelligence, genomics, and computational biology to reduce development risk and accelerate clinical trial processes. Lantern has established collaborations with academic institutions and clinical translational centers to validate drug activity and identify associated gene signatures.

In January 2026, Lantern introduced withZeta.ai, a generative AI platform designed to accelerate rare cancer research and drug development by combining proprietary knowledge bases with autonomous task completion. The company also offers PredictBBB, a web application predicting blood-brain barrier permeability with 94% accuracy. Lantern plans to commercialize select RADR® AI modules and related technologies as revenue-generating services for the broader research and drug development community through subscriptions and collaborative partnerships. The company maintains an extensive multi-national intellectual property portfolio comprising over 200 active patents and patent applications across 20 patent families. More information is available at www.lanternpharma.com.